Recent advances in immunotherapy for cancer have led to the licensing of new biotherapeutics for prostate cancer and melanoma. However, there is a general recognition that immunotherapy alone will not be sufficient to deliver benefit to all patients.
New combinations of immunotherapy and drug treatments have led slowly to the concept that some commonly used drugs may synergize with immunotherapy. There is increasing in vitro and in vivo evidence to support the emerging concept of chemotherapy/immunotherapy combinations for cancer.
The Cancer Vaccine Institute’s second International Symposium on Immunotherapy will be held at The Royal Society in London on the 15 – 16 May 2015.
Following the success of our first symposium held in October 2013, we have been asked to organise another such event. This important two day symposium will explore key areas of research into synergism between immunotherapy and standard treatments in oncology and will offer an unparalleled opportunity for the international research and clinical community to come together and explore the opportunities and challenges that exist today in immunotherapy.
Key themes of the symposium will be:
- How chemotherapy alters the immunogenicity of tumour cells
- The effects of chemotherapy on immune regulation
- How chemotherapy can be combined to best effect with vaccines or other immunotherapy
- Clinical studies exploring the combinations of chemotherapy and immunotherapy
Professor Philipp Beckhove
German Cancer Research Center